KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies
[Paper-level Aggregated] PMCID: PMC4884999
Evidence Type(s): Oncogenic
Summary: Mutation: G12C | Summary: The G12C mutation in KRAS is identified as a common mutation occurring in codon 12, which contributes to tumor development or progression in lung cancer.
Gene→Variant (gene-first): KRAS(3845):G12C
Genes: KRAS(3845)
Variants: G12C
Based on our search criteria, a total of 41 studies, which enrolled 13,103 KRAS assessable patients with 18 percent (2,374) KRAS mutant positive cases, were eligible for inclusion in the present analyses. The process of
[Paragraph-level] PMCID: PMC4884999 Section: RESULTS PassageIndex: 3
Evidence Type(s): Oncogenic
Summary: Evidence Type: Oncogenic | Mutation: G12C | Summary: The G12C mutation in KRAS is identified as a common mutation occurring in codon 12, which contributes to tumor development or progression in lung cancer.
Gene→Variant (gene-first): 3845:G12C
Genes: 3845
Variants: G12C
KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies
[Paper-level Aggregated] PMCID: PMC4884999
Evidence Type(s): Oncogenic, Predictive
Justification: Oncogenic: The text indicates that the majority of KRAS mutations occur in codon 12, with G12C being the most common, suggesting its role in cancer development. Predictive: The mention of KRAS mutations, including G12C, in the context of studies focused on NSCLC implies that these mutations may predict response to targeted therapies.
Gene→Variant (gene-first): KRAS(3845):G12C
Genes: KRAS(3845)
Variants: G12C
Based on our search criteria, a total of 41 studies, which enrolled 13,103 KRAS assessable patients with 18 percent (2,374) KRAS mutant positive cases, were eligible for inclusion in the present analyses. The process of
[Paragraph-level] PMCID: PMC4884999 Section: RESULTS PassageIndex: 3
Evidence Type(s): Diagnostic, Oncogenic
Justification: Diagnostic: The passage discusses the frequency of KRAS mutations, specifically mentioning that the majority occur in codon 12 with G12C being the most common, indicating its association with lung cancer subtypes. Oncogenic: The mention of KRAS mutations, including G12C, in the context of lung adenocarcinoma suggests that this somatic variant contributes to tumor development or progression.
Gene→Variant (gene-first): 3845:G12C
Genes: 3845
Variants: G12C
Based on our search criteria, a total of 41 studies, which enrolled 13,103 KRAS assessable patients with 18 percent (2,374) KRAS mutant positive cases, were eligible for inclusion in the present analyses. The process of
[Paragraph-level] PMCID: PMC4884999 Section: RESULTS PassageIndex: 3
Evidence Type(s): Diagnostic, Oncogenic
Justification: Diagnostic: The passage discusses the frequency of KRAS mutations, specifically mentioning that the majority occur in codon 12 with G12C being the most common, indicating its association with lung cancer subtypes. Oncogenic: The mention of KRAS mutations, including G12C, in the context of lung adenocarcinoma suggests that this somatic variant contributes to tumor development or progression.
Gene→Variant (gene-first): 3845:G12C
Genes: 3845
Variants: G12C